跳到主要內容

臺灣博碩士論文加值系統

(18.97.9.172) 您好!臺灣時間:2025/02/11 14:46
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:廖祈然
研究生(外文):Chi-Jan Liao
論文名稱:探討淋巴球細胞中脂蛋白脂解酶表現量及活性與致高三酸甘油酯危險性及保護性單套型之相關性
論文名稱(外文):The correlation between lipoprotein lipase(LPL) haplotypes for triglyceride elevation and LPL expression and activity in lymphocyte
指導教授:潘文涵潘文涵引用關係
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:微生物與生化學研究所
學門:生命科學學門
學類:微生物學類
論文種類:學術論文
論文出版年:2007
畢業學年度:95
語文別:中文
中文關鍵詞:高三酸甘油酯血症脂蛋白脂解酶危險性單套型保護性單套型脂肪酸淋巴球細胞
外文關鍵詞:hypertriglyceridemialipoprotein lipaserisk haplotypesprotective haplotypesfatty acidslymphocytes
相關次數:
  • 被引用被引用:0
  • 點閱點閱:223
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
高三酸甘油酯血症是一種常見的多重因素疾病,目前對其致病機轉仍未完全清楚。過去曾有研究指出當人體內脂蛋白脂解酶基因發生變異時,易導致血液中三酸甘油酯濃度增加,進而造成高三酸甘油酯血症。本研究室過去發現兩個脂蛋白脂解酶上的基因單套型與血中三酸甘油酯濃度增加有顯著的相關性,稱之為致高三酸甘油酯危險性單套型,而相對應於危險性單套型的則稱之為保護性單套型。因此本研究主要是利用(1)帶有致高三酸甘油酯危險性單套體的淋巴球細胞;及(2)帶有致高三酸甘油酯保護性單套體的淋巴球細胞,以試管內實驗探討脂蛋白脂解酶基因若帶有此致高三酸甘油酯危險性單套型,是否會影響人體內脂蛋白脂解酶的蛋白質表現量及活性。而此實驗方法是在一般培養液下培養三天後,收集細胞萃取液並比較兩組細胞間的脂蛋白脂解酶蛋白質表現量及活性。此外兩組細胞皆分別加入油酸、花生油四烯酸、亞麻油酸與二十碳五烯酸100、200、300及400μM,培養24小時後,收集細胞萃取液並比較兩組細胞間的脂蛋白脂解酶蛋白質表現量及活性是否會因基因型不同而不同。由實驗結果發現無論有沒有經過脂肪酸的處理,兩組細胞間細胞中的脂蛋白脂解酶蛋白質表現量都沒有顯著差異。但帶有致高三酸甘油酯危險性單套型的淋巴球細胞內之脂蛋白脂解酶基本活性顯著高於帶有保護性單套體的淋巴球細胞(P=0.0002)。且經過脂肪酸處理24小時之後,兩組細胞內的脂蛋白脂解酶活性都會受到脂肪酸的抑制,其中在油酸及花生油四烯酸處理後,帶有致高三酸甘油酯危險性單套型的淋巴球細胞內之脂蛋白脂解酶受到的抑制效果顯著高於帶有保護性單套型的淋巴球細胞(油酸及亞麻油酸的P值分別為0.045及0.006)。綜合以上結果可見兩組細胞間雖然蛋白質表現量沒有顯著差異,但基本活性及受脂肪酸的調控都不同,顯示帶有致高三酸甘油酯危險性及保護性單套型的淋巴球細胞間脂蛋白脂解酶在功能上是有差異的,但此功能上的差異如何會導致高三酸甘油酯仍待進一步的實驗來釐清。
Hypertriglyceridemia is a common, multifactorial metabolic disorder. The pathogenesis of this disease is not altogether clear, but it clearly involves in genetic variation of lipoprotein lipase(LPL), a key enzyme in lipid metabolism. Pei et al preciously reported that two LPL variants with significant proportion(15-21%) were significantly associated with hypertriglyceridemia, called risk haplotypes. Therefore, the aim of this in-vitro experiment was to investigate that if these risk halotypes on LPL had any influence on the LPL protein expression and activity level. Four immortalized lymphocyte cell lines were used in the present study: two lines carried both risk haplotypes and two lines carried both protective haplotypes for hypertriglyceridemia. Basal level of LPL protein expression and activity were measured in both groups of cell lines. Then, lymphocytes in both groups were cultured for 24 h with 0.1, 0.2, 0.3 and 0.4 mmol/L unsaturated fatty acids(oleic acid[OA], arachidonic acid[AA], linoleic acid[LA] and eicosapentaenoic acid[EPA])and lymphocyte LPL protein expression and activity were measured at the end of this incubation period. The results show that there was no significant difference in LPL protein expression between lymphocytes with protective and with risk haplotypes whether or not they were treated with fatty acids. However, the basal level of LPL activity were higher in lymphocytes with risk haplotypes than in those with protective haplotypes(P=0.0002). Furthermore, incubation of lymphocytes with fatty acids decreased LPL activity in both groups and the inhibition of LPL activity are stronger in lymphocytes with risk haplotypes after OA and AA treatment. Overall, these results demonstrated that the basal level of LPL activity was higher and the inhibition of LPL activity is stronger in lymphocytes with risk haplotypes after fatty acids treatment than its counterpart. The difference in LPL activity suggested that the function of LPL is different in lymphocytes with risk and in those with protective haplotypes, but how does the functional difference cause hypertriglyceridemia needs further studies.
口試委員審定書 ...................................
中文摘要........................................ I
英文摘要.........................................III
第一章、 文獻回顧...............................................3
第一節 高三酸甘油酯血症之流行病學...............................................3
第二節 高三酸甘油酯遺傳研究現況...............................................5
第三節 脂蛋白脂解酶...............................................8
一、 脂蛋白脂解酶的基本特性與功能...............................................8
二、 脂蛋白脂解酶的分泌機轉...............................................9
三、 脂蛋白脂解酶的基因結構...............................................10
四、 脂蛋白脂解酶的基因調控...............................................11
第四節 脂蛋白脂解酶與高血壓之相關性...............................................12
第五節 脂蛋白脂解酶與高三酸甘油脂之相關性...............................................14
第二章、 研究動機與目的...............................................16
第三章、 材料與方法...............................................18
第一節 實驗設計...............................................18
第二節 實驗材料...............................................18
一、 細胞株...............................................18
二、 抗體........................................19
三、 試劑........................................19
第三節 脂肪酸特性................................20
一、油酸鈉(Sodium oleate,OA):................20
二、亞麻油酸鈉(Linoleic acid sodium salt,LA):20
三、花生四烯酸鈉(Arachidonic acid sodium salt,AA): .......................................21
四、二十碳五烯酸鈉(Eicosapentaenoic acid sodium salt,EPA):..........................................21
第四節 實驗方法..................................21
一、細胞培養.....................................22
二、細胞萃取液的製備(preparation of cell lysates)
................................................22
三、蛋白質定量...................................22
四、聚丙烯醯胺膠電泳(Polyacrylamide gel electrophoresis PAGE)與西方點墨法(Western blotting)........................................22
五、脂肪酸對脂蛋白脂解酶表現的影響...............23
六、脂蛋白脂解酶活性分析(LPL activity assay)...24
第五節 統計分析..................................25
第四章、 研究結果................................26
第一節 不同細胞間細胞型態的比較..................26
第二節 脂蛋白脂解酶蛋白質表現量分析..............26
第三節 脂蛋白脂解酶活性分析......................28
第五章、 討論....................................30
第六章、 參考文獻................................43
1. 行政院衛生署: 民國九十四年死因統計結果. http://www.doh.gov.tw/cht2006/index_populace.aspx.
2. Pejic RN, Lee DT: Hypertriglyceridemia. J Am Board Fam Med 2006, 19:310-316.
3. Kagan A, Harris BR, Winkelstein W, Jr., Johnson KG, Kato H, Syme SL, Rhoads GG, Gay ML, Nichaman MZ, Hamilton HB, et al.: Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. J Chronic Dis 1974, 27:345-364.
4. Gordon T, Kannel WB, Castelli WP, Dawber TR: Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981, 141:1128-1131.
5. Anderson KM, Castelli WP, Levy D: Cholesterol and mortality. 30 years of follow-up from the Framingham study. Jama 1987, 257:2176-2180.
6. Castelli WP, Anderson K: A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med 1986, 80:23-32.
7. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
8. Austin MA, Hokanson JE, Edwards KL: Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998, 81:7B-12B.
9. Fung MA, Frohlich JJ: Common problems in the management of hypertriglyceridemia. Cmaj 2002, 167:1261-1266.
10. Gouni-Berthold I, Krone W: Hypertriglyceridemia-why, when and how should it be treated? Z Kardiol 2005, 94:731-739.
11. Guerra R, Wang J, Grundy SM, Cohen JC: A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A 1997, 94:4532-4537.
12. van''t Hooft FM, Lundahl B, Ragogna F, Karpe F, Olivecrona G, Hamsten A: Functional characterization of 4 polymorphisms in promoter region of hepatic lipase gene. Arterioscler Thromb Vasc Biol 2000, 20:1335-1339.
13. Deeb SS, Peng R: The C-514T polymorphism in the human hepatic lipase gene promoter diminishes its activity. J Lipid Res 2000, 41:155-158.
14. Xin X, Srinivasan SR, Chen W, Boerwinkle E, Berenson GS: Interaction effect of Serine447Stop variant of the lipoprotein lipase gene and C-514T variant of the hepatic lipase gene on serum triglyceride levels in young adults: the Bogalusa Heart Study. Metabolism 2003, 52:1337-1342.
15. Lam CW, Yuen YP, Cheng WF, Chan YW, Tong SF: Missense mutation Leu72Pro located on the carboxyl terminal amphipathic helix of apolipoprotein C-II causes familial chylomicronemia syndrome. Clin Chim Acta 2006, 364:256-259.
16. Shachter NS: Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001, 12:297-304.
17. Hallman DM, Srinivasan SR, Chen W, Boerwinkle E, Berenson GS: Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study. Metabolism 2006, 55:1574-1581.
18. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001, 294:169-173.
19. Zhao SP, Hu S, Li J, Hu M, Liu Q, Wu LJ, Zhang T: Association of human serum apolipoprotein A5 with lipid profiles affected by gender. Clin Chim Acta 2007, 376:68-71.
20. Lai CQ, Tai ES, Tan CE, Cutter J, Chew SK, Zhu YP, Adiconis X, Ordovas JM: The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J Lipid Res 2003, 44:2365-2373.
21. Kao JT, Wen HC, Chien KL, Hsu HC, Lin SW: A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 2003, 12:2533-2539.
22. Dallongeville J, Lussier-Cacan S, Davignon J: Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992, 33:447-454.
23. Ferre P: The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53 Suppl 1:S43-50.
24. Lee CH, Olson P, Evans RM: Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003, 144:2201-2207.
25. Garenc C, Aubert S, Laroche J, Girouard J, Vohl MC, Bergeron J, Rousseau F, Julien P: Population prevalence of APOE, APOC3 and PPAR-alpha mutations associated to hypertriglyceridemia in French Canadians. J Hum Genet 2004, 49:691-700.
26. Williams RR, Hunt SC, Hopkins PN, Wu LL, Lalouel JM: Evidence for single gene contributions to hypertension and lipid disturbances: definition, genetics, and clinical significance. Clin Genet 1994, 46:80-87.
27. Sprecher DL, Harris BV, Stein EA, Bellet PS, Keilson LM, Simbartl LA: Higher triglycerides, lower high-density lipoprotein cholesterol, and higher systolic blood pressure in lipoprotein lipase-deficient heterozygotes. A preliminary report. Circulation 1996, 94:3239-3245.
28. Hopkins PN, Heiss G, Ellison RC, Province MA, Pankow JS, Eckfeldt JH, Hunt SC: Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 2003, 108:519-523.
29. Shieh SM, Shen M, Fuh MM, Chen YD, Reaven GM: Plasma lipid and lipoprotein concentrations in Chinese males with coronary artery disease, with and without hypertension. Atherosclerosis 1987, 67:49-55.
30. Mead JR, Irvine SA, Ramji DP: Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 2002, 80:753-769.
31. Braun JE, Severson DL: Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem J 1992, 287 ( Pt 2):337-347.
32. Beisiegel U, Weber W, Bengtsson-Olivecrona G: Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci U S A 1991, 88:8342-8346.
33. Iverius PH, Ostlund-Lindqvist AM: Lipoprotein lipase from bovine milk. Isolation procedure, chemical characterization, and molecular weight analysis. J Biol Chem 1976, 251:7791-7795.
34. Vannier C, Ailhaud G: Biosynthesis of lipoprotein lipase in cultured mouse adipocytes. II. Processing, subunit assembly, and intracellular transport. J Biol Chem 1989, 264:13206-13216.
35. Ben-Zeev O, Doolittle MH, Davis RC, Elovson J, Schotz MC: Maturation of lipoprotein lipase. Expression of full catalytic activity requires glucose trimming but not translocation to the cis-Golgi compartment. J Biol Chem 1992, 267:6219-6227.
36. Sparkes RS, Zollman S, Klisak I, Kirchgessner TG, Komaromy MC, Mohandas T, Schotz MC, Lusis AJ: Human genes involved in lipolysis of plasma lipoproteins: mapping of loci for lipoprotein lipase to 8p22 and hepatic lipase to 15q21. Genomics 1987, 1:138-144.
37. Wion KL, Kirchgessner TG, Lusis AJ, Schotz MC, Lawn RM: Human lipoprotein lipase complementary DNA sequence. Science 1987, 235:1638-1641.
38. Enerback S, Gimble JM: Lipoprotein lipase gene expression: physiological regulators at the transcriptional and post-transcriptional level. Biochim Biophys Acta 1993, 1169:107-125.
39. Doolittle MH, Ben-Zeev O, Elovson J, Martin D, Kirchgessner TG: The response of lipoprotein lipase to feeding and fasting. Evidence for posttranslational regulation. J Biol Chem 1990, 265:4570-4577.
40. Ong JM, Kirchgessner TG, Schotz MC, Kern PA: Insulin increases the synthetic rate and messenger RNA level of lipoprotein lipase in isolated rat adipocytes. J Biol Chem 1988, 263:12933-12938.
41. Fried SK, Russell CD, Grauso NL, Brolin RE: Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. J Clin Invest 1993, 92:2191-2198.
42. Semenkovich CF, Wims M, Noe L, Etienne J, Chan L: Insulin regulation of lipoprotein lipase activity in 3T3-L1 adipocytes is mediated at posttranscriptional and posttranslational levels. J Biol Chem 1989, 264:9030-9038.
43. Sartippour MR, Lambert A, Laframboise M, St-Jacques P, Renier G: Stimulatory effect of glucose on macrophage lipoprotein lipase expression and production. Diabetes 1998, 47:431-438.
44. Clee SM, Loubser O, Collins J, Kastelein JJ, Hayden MR: The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clin Genet 2001, 60:293-300.
45. Michaud SE, Renier G: Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: potential role of PPARs. Diabetes 2001, 50:660-666.
46. Amri EZ, Teboul L, Vannier C, Grimaldi PA, Ailhaud G: Fatty acids regulate the expression of lipoprotein lipase gene and activity in preadipose and adipose cells. Biochem J 1996, 314 ( Pt 2):541-546.
47. Hunt SC, Province MA, Atwood LD, Sholinsky P, Lalouel JM, Rao DC, Williams RR, Leppert MF: No linkage of the lipoprotein lipase locus to hypertension in Caucasians. J Hypertens 1999, 17:39-43.
48. Wu SY, Fann CS, Jou YS, Chen JW, Pan WH: Association between markers in chromosomal region 17q23 and young onset hypertension: a TDT study. J Med Genet 2002, 39:42-44.
49. Pan WH, Chen JW, Fann C, Jou YS, Wu SY: Linkage analysis with candidate genes: the Taiwan young-onset hypertension genetic study. Hum Genet 2000, 107:210-215.
50. 陳珮: 台灣年輕型高血壓遺傳研究:脂蛋白脂解酶基因與高血壓相關徵狀之關係. 國防醫學院生命科學研究所博士論文 2005.
51. Langlois S, Deeb S, Brunzell JD, Kastelein JJ, Hayden MR: A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency. Proc Natl Acad Sci U S A 1989, 86:948-952.
52. Evans V, Kastelein JJ: Lipoprotein lipase deficiency--rare or common? Cardiovasc Drugs Ther 2002, 16:283-287.
53. Wittekoek ME, Pimstone SN, Reymer PW, Feuth L, Botma GJ, Defesche JC, Prins M, Hayden MR, Kastelein JJ: A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation 1998, 97:729-735.
54. Fisher RM, Humphries SE, Talmud PJ: Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atherosclerosis 1997, 135:145-159.
55. Wittekoek ME, Moll E, Pimstone SN, Trip MD, Lansberg PJ, Defesche JC, van Doormaal JJ, Hayden MR, Kastelein JJ: A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999, 19:2708-2713.
56. Wung SF, Kulkarni MV, Pullinger CR, Malloy MJ, Kane JP, Aouizerat BE: The lipoprotein lipase gene in combined hyperlipidemia: evidence of a protective allele depletion. Lipids Health Dis 2006, 5:19.
57. Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg-Hansen A: Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 1997, 96:1737-1744.
58. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG: Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999, 99:2901-2907.
59. van Bockxmeer FM, Liu Q, Mamotte C, Burke V, Taylor R: Lipoprotein lipase D9N, N291S and S447X polymorphisms: their influence on premature coronary heart disease and plasma lipids. Atherosclerosis 2001, 157:123-129.
60. Templeton AR: Cladistic approaches to identifying determinants of variability in multifactorial phenotypes and the evolutionary significance of variation in the human genome. Ciba Found Symp 1996, 197:259-277; discussion 277-283.
61. Jump DB: The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002, 277:8755-8758.
62. Montalto MB, Bensadoun A: Lipoprotein lipase synthesis and secretion: effects of concentration and type of fatty acids in adipocyte cell culture. J Lipid Res 1993, 34:397-407.
63. Duque M, Graupner M, Stutz H, Wicher I, Zechner R, Paltauf F, Hermetter A: New fluorogenic triacylglycerol analogs as substrates for the determination and chiral discrimination of lipase activities. J Lipid Res 1996, 37:868-876.
64. Vannier C, Amri EZ, Etienne J, Negrel R, Ailhaud G: Maturation and secretion of lipoprotein lipase in cultured adipose cells. I. Intracellular activation of the enzyme. J Biol Chem 1985, 260:4424-4431.
65. Edwards K, Chan RY, Sawyer WH: Interactions between fatty acids and lipoprotein lipase: specific binding and complex formation. Biochemistry 1994, 33:13304-13311.
66. Murphy MC, Zampelas A, Puddicombe SM, Furlonger NP, Morgan LM, Williams CM: Pretranslational regulation of the expression of the lipoprotein lipase (EC 3.1.1.34) gene by dietary fatty acids in the rat. Br J Nutr 1993, 70:727-736.
67. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J: PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. Embo J 1996, 15:5336-5348.
68. Ren B, Thelen AP, Peters JM, Gonzalez FJ, Jump DB: Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor alpha. J Biol Chem 1997, 272:26827-26832.
69. Faustinella F, Chang A, Van Biervliet JP, Rosseneu M, Vinaimont N, Smith LC, Chen SH, Chan L: Catalytic triad residue mutation (Asp156----Gly) causing familial lipoprotein lipase deficiency. Co-inheritance with a nonsense mutation (Ser447----Ter) in a Turkish family. J Biol Chem 1991, 266:14418-14424.
70. Kobayashi J, Nishida T, Ameis D, Stahnke G, Schotz MC, Hashimoto H, Fukamachi I, Shirai K, Saito Y, Yoshida S: A heterozygous mutation (the codon for Ser447----a stop codon) in lipoprotein lipase contributes to a defect in lipid interface recognition in a case with type I hyperlipidemia. Biochem Biophys Res Commun 1992, 182:70-77.
71. Previato L, Guardamagna O, Dugi KA, Ronan R, Talley GD, Santamarina-Fojo S, Brewer HB, Jr.: A novel missense mutation in the C-terminal domain of lipoprotein lipase (Glu410-->Val) leads to enzyme inactivation and familial chylomicronemia. J Lipid Res 1994, 35:1552-1560.
72. Kozaki K, Gotoda T, Kawamura M, Shimano H, Yazaki Y, Ouchi Y, Orimo H, Yamada N: Mutational analysis of human lipoprotein lipase by carboxy-terminal truncation. J Lipid Res 1993, 34:1765-1772.
73. Ross CJ, Liu G, Kuivenhoven JA, Twisk J, Rip J, van Dop W, Excoffon KJ, Lewis SM, Kastelein JJ, Hayden MR: Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arterioscler Thromb Vasc Biol 2005, 25:2143-2150.
74. Kastelein JJ, Jukema JW, Zwinderman AH, Clee S, van Boven AJ, Jansen H, Rabelink TJ, Peters RJ, Lie KI, Liu G, et al.: Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group. Circulation 2000, 102:1629-1633.
75. Beauchamp MC, Renier G: Homocysteine induces protein kinase C activation and stimulates c-Fos and lipoprotein lipase expression in macrophages. Diabetes 2002, 51:1180-1187.
76. Maingrette F, Renier G: Leptin increases lipoprotein lipase secretion by macrophages: involvement of oxidative stress and protein kinase C. Diabetes 2003, 52:2121-2128.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊